Author Archives: Ben Comer

Momenta CEO Rebuffs Teva's Copaxone Defense

Momenta Pharmaceuticals’ CEO Craig Wheeler said comments made by Teva leadership about a “purported” generic of Copaxone are “kind of humorous.” Teva’s Copaxone, a multiple sclerosis drug that earns nearly $4 billion a year, is approaching patent expiry – and possible generic competition – on May 24. Assuming FDA approves a generic version of Copaxone, […]
Posted in Biotech, FDA, IP, leadership, Legal, People, pricing, R&D, Regulatory, Strategy | Tagged , , , , , , , | Leave a comment

IMS's Top 10 Pharma Social Media Engagers

The IMS Institute for Healthcare Informatics worked up a methodology for assessing the effectiveness of pharma’s social media efforts across Facebook, Twitter and YouTube, according to three indices: reach (total number of people reached through each channel via likes, shares and re-tweets); relevance (extent to which content is being shared and forwarded); and relationship (amount […]
Posted in Advertising, E-Media, leadership, Marketing, patient education, Regulatory, social media, Strategy, Technology | Tagged | 1 Comment

J.P. Morgan: Pharma's Agenda for 2014

Presenters at the 32nd annual J.P. Morgan Healthcare Conference talked up value-based pricing, emerging market strategies, complex generics and new technology, from bedside devices and genetic sequencers to first-in-class mechanisms of action. Company executives honed in on their chosen therapeutic areas and made the case for aggressive spending in R&D to bring the next generation […]
Posted in Biotech, Corporate Responsibility, Deals, Emerging Markets, Europe, Events, FDA, Gene therapy, Global, IP, leadership, Legal, Manufacturing, Market Access, Orphan Drugs, People, pricing, R&D, Regulatory, Safety, Sales, Strategy, Technology | Tagged , , , , , , , , , , , , , , , , , | Leave a comment

Confessions of a Compliance Director

In anticipation of CBI’s (a PharmExec sibling company) 11th Annual Pharma Compliance Congress happening later this month, PharmExec spoke with a compliance director at a mid-sized pharma ($5 billion in annual sales) about life under a CIA, and the potential trigger issues for 2014. In an effort to promote candor and avoid overly circumspect responses, […]
Posted in compliance, Corporate Responsibility, E-Media, Emerging Markets, FDA, healthcare, Legal, Marketing, Medical Education, pricing, Regulatory, Sales, social media, Strategy | Tagged , , , , , , , , , , , , , , | Leave a comment

Best of the Blog: PharmExec's 10 Most Read Stories in 2013

Happy New Year! We at PharmExec are looking forward to a busy and hopefully fortuitous 2014. For our colleagues in the Northeast bracing for yet another snow storm – and for those of you with better short-term environmental prospects – here are the 10 most-read stories published on PharmExec‘s blog during 2013, in case you […]
Posted in Advertising, Biotech, Emerging Markets, Europe, FDA, Global, Guest Blog, healthcare, IP, Legal, Market Access, People, pricing, R&D, Regulatory, Strategy, Technology | Tagged , , , , , , , , , , , , , | Leave a comment
  • Categories

  • Meta